The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to brensocatib, marketed as Brinsupri, for the treatment of patients aged 12 years and older with Non-Cystic Fibrosis Bronchiectasis (NCFB) who have experienced at least two exacerbations in the past 12 months. The approval was issued on February 20th, 2026 to Insmed Netherlands B.V.

Non-cystic fibrosis bronchiectasis is a chronic respiratory condition characterised by permanent damage to the airways, leading to persistent cough and mucus production. While it can affect individuals of all ages, it is more commonly diagnosed in older adults.

Brensocatib works by inhibiting dipeptidyl peptidase 1 (DPP1), a protein involved in the inflammatory process in the lungs. By blocking DPP1 activity, the medicine helps reduce flare-ups and may improve symptoms associated with the disease. It is administered orally as a once-daily tablet.

Julian Beach, Executive Director of Healthcare Quality and Access at the MHRA, said the approval marks the first licensed medicine in the UK specifically indicated for NCFB, adding that the agency will continue to closely monitor its safety and effectiveness.

Common side effects reported with brensocatib include upper respiratory tract infections, diarrhoea, vomiting, headache, gum-related issues, hyperkeratosis, rash, dermatitis and alopecia. Detailed safety information will be available in the Patient Information Leaflet and Summary of Product Characteristics on the MHRA website within seven days of approval.

Patients experiencing suspected side effects are encouraged to consult healthcare professionals and report them through the MHRA’s Yellow Card scheme.